Aclaris Therapeutics (ACRS) Non-Current Deferred Tax Liability (2017 - 2023)
Historic Non-Current Deferred Tax Liability for Aclaris Therapeutics (ACRS) over the last 7 years, with Q3 2023 value amounting to $367000.0.
- Aclaris Therapeutics' Non-Current Deferred Tax Liability changed 0.0% to $367000.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $367000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $367000.0 for FY2022, which is 0.0% changed from last year.
- Per Aclaris Therapeutics' latest filing, its Non-Current Deferred Tax Liability stood at $367000.0 for Q3 2023, which was down 0.0% from $367000.0 recorded in Q2 2023.
- In the past 5 years, Aclaris Therapeutics' Non-Current Deferred Tax Liability registered a high of $549000.0 during Q1 2019, and its lowest value of $367000.0 during Q4 2020.
- For the 5-year period, Aclaris Therapeutics' Non-Current Deferred Tax Liability averaged around $434052.6, with its median value being $367000.0 (2020).
- Its Non-Current Deferred Tax Liability has fluctuated over the past 5 years, first changed by 0.0% in 2019, then crashed by 3315.12% in 2020.
- Quarter analysis of 5 years shows Aclaris Therapeutics' Non-Current Deferred Tax Liability stood at $549000.0 in 2019, then crashed by 33.15% to $367000.0 in 2020, then changed by 0.0% to $367000.0 in 2021, then changed by 0.0% to $367000.0 in 2022, then changed by 0.0% to $367000.0 in 2023.
- Its Non-Current Deferred Tax Liability was $367000.0 in Q3 2023, compared to $367000.0 in Q2 2023 and $367000.0 in Q1 2023.